Boundless Bio
Focus: Boundless Bio is a San Diego-based oncology-focused biotech developing novel cancer treatments targeting extra-chromosomal DNA, a distinctive mechanism in the solid tumor space. The company operates as a pre-revenue biotech with an early-stage pipeline.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Open Jobs
2-2 this month
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Should You Work at Boundless Bio?
AI assessmentBoundless Bio is a high-risk, high-innovation early-stage play best suited for scientists and business developers willing to accept pre-revenue uncertainty for meaningful early-stage impact.
Why Work Here
- Opportunity to work on a novel oncology mechanism (extra-chromosomal DNA targeting) that differentiates the company in a crowded cancer therapy market.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BBI-825
Solid TumorClinical Trials (1)
NCT06299761Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
Phase 1Help build intelligence for Boundless Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.